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Case Report
 INTRODUCTION 
Intralabyrinthine schwannoma (ILS) is a rare benign tumor that affects the ends of cochlear and vestibular nerves. It involves the 
vestibule, cochlea, or semicircular canal [1]. ILS was first described by Meter in 1917 with a temporal bone study in a patient with 
Von Recklinghausen syndrome. In the same year, an autopsy-based report described a schwannoma isolated in the scala tympani 
of a patient with normal hearing [2]. ILS symptoms are rather unspecific. In a majority of cases it occurs with unilateral sensorineural 
hearing loss, which is frequently progressive and in some cases, sudden or fluctuating. Less frequent symptoms include tinnitus 
(51%), imbalance (35%), vertigo (22%), or fullness (2%), alone or in combination [3]. An accurate assessment for differential diagnosis 
from other inner ear disorders, such as Menière’s disease or vestibular neuritis, is necessary. The lack of specific symptoms and slow 
growth pattern explain why the diagnosis is often delayed. Today, the advent of magnetic resonance imaging (MRI) allows early di-
agnosis, enabling an appropriate therapeutic protocol. The present report describes a case of intravestibular schwannoma confined 
to the vestibular cavity, without extension into the semicircular canals, with fluctuating hearing loss and intractable vertigo that 
demanded the use of intratympanic gentamicin.
CASE PRESENTATION 
A 28 year-old woman with intractable vertigo and fluctuating left-side hearing loss for 1 month was admitted to our clinic. There 
was no history of ear drainage or pain, and the otoscopic examination was negative on the left and right side. No spontaneous 
nystagmus was observed. Romberg test proved negative, and neurological functions were normal. Audiometric tests showed 
moderate sensorineural hearing loss at low frequencies (Figure 1a) and slight reduction of detection threshold without alter-
ation in word discrimination on the left side (Figure 1b). Electrocochleography did not reveal a hydropic component (summating 
potential/action potential=0.32). Video Head Impulse Test (vHIT) showed slight hyporeflexia on the affected side. Oral steroid 
treatment (1 mg/kg for 10 days) was immediately initiated with improvement of the patient’s vertigo and hearing symptoms 
(Figure 2), which recurred at the end of the treatment. On enhanced T1-weighted images of a gadolinium-enhanced MRI (Gd-
MRI), the presence of a 2×3 mm mass was observed to be confined to the vestibule on the left side without extension into the 
semicircular canals and with hyper-intensity on T2-weighted sequences (Figure 3a, b). Because surgery was temporarily exclud-
ed to avoid hearing loss and due to the patient’s refusal, we proposed a single dose of 0.4 cc intratympanic gentamicin (40 mg/
mL) [Gentamicina solfato, Fisipharma, Nucleo Industriale Palomonte (SA), Italy] buffered with sodium bicarbonate. The patient 
signed the informed consent form for treatment with intratympanic gentamicin. Following the treatment, the patient showed 
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a significant improvement in her symptoms with disappearance of 
vertigo. vHIT showed severe hyporeflexia on the affected side and 
controlateral normoreflexia; audiometric tests showed moderate, 
flat sensorineural hearing loss (Figure 4a) and a reduction in speech 
discrimination (90% at 85 dB) (Figure 4b). Vestibular symptoms 
were substantially unvaried. However, audiometric tests showed 
slight additional hearing and speech discrimination deterioration 
3 months after treatment (Figure 5a, b). After 6 months, The patient 
reported no further vertigo episodes, a moderate improvement 
in hearing threshold, and speech discrimination of 90% at 60 dB 
(Figure 6a, b). After 1 year, she underwent an MRI that showed no 
growth of the tumor lesion (Figure 7) and stability of the auditory 
condition. 
DISCUSSION
Intralabyrinthine schwannoma is a rare pathology; however, its in-
cidence has increased in recent years due to the advent of sophis-
ticated imaging techniques. MRI is the current gold standard for its 
diagnosis, showing lesions with neat margins, hyperintense in T1 
and hypointense in T2. MRI could be used for preoperative localiza-
tion and surgical planning, as well as for following-up the eventual 
growth of tumors [1]. 
Kennedy divided ILS into 7 types according to its localization: intraco-
chlear, intravestibular, intracochleo–vestibular, transmacular, transmo-
diolar, tympano–labyrinthine, and transotic. In 2013, Van Abel et al. [3] 
Figure 1. a, b. (a) Pure tone audiometry before treatment. (b) Headphone speech discrimination before treatment.
a b
Figure 3. a, b. (a) Axial T1-weighted MR images show noticeable nodular ves-
tibular mass enhancement after contrast administration. (b) Axial T2-weight-
ed MR images of the internal auditory canal, cochlea, and eighth cranial 
nerve. It is possible to identify a lack of natural hyper-intense signal in the 
vestibule due to the presence of a small nodule.
b
a
Figure 2. Pure tone audiometry after oral steroids.
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Figure 4. a, b. (a)Pure tone audiometry 1 month after gentamicin treatment. (b) Headphone speech discrimination 1 month after gentamicin treatment.
a b
Figure 5. a, b. (a) Pure tone audiometry 3 months after gentamicin treatment. (b) Headphone speech discrimination 3 months after gentamicin treatment.
a b
Figure 6. a, b. (a) Pure tone audiometry 6 months after gentamicin treatment. (b) Headphone speech discrimination 6 months after gentamicin treatment.
a b
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added 2 more types: trans-labyrinthine and transotic variant into the 
cerebellopontine angle. 
Management options primarily include serial observations with MRI 
(wait and scan approach) because this tumor usually grows very 
slowly and with few symptoms. 
Surgical removal is reserved to a limited number of cases and 
mostly depends on age, general condition of the patient, tumor 
size, location and growth (into the internal auditory canal or mid-
dle ear), and the presence of intractable symptoms (vertigo). Sur-
gical ablative treatment would result in total hearing loss in 100% 
of cases, with some likelihood of facial nerve palsy in 4% of cas-
es, cerebrospinal fluid leakage in 5.4% of cases, and meningitis in 
1.8% of cases [4]. In a recent review regarding ILS, among 53% of 
patients (109 of 189) observed using serial MRI scans, only 3% re-
quired surgical removal [3], supporting the adoption of the wait and 
scan approach. 
To the authors’ knowledge, only 2 patients have been reported to re-
ceive stereotactic radiosurgery for ILS. This treatment has the same 
indication as surgical treatment and is mostly indicated for those pa-
tients who cannot undergo surgery due to general counter-indica-
tions. However, it does not seem to be effective for vertigo, adding to 
the possibility of neurological effects and malignant transformations 
of the tumor [5].
Transtympanic steroid injection has also been reported in a patient 
with ILS and sudden sensorineural hearing loss, without vertigo or 
dizziness [6]. The patient of the present report presented with intrac-
table vertigo and fluctuating left-side hearing loss. Therefore, after 
the patient refused surgery, a single-dose of 40 mg/ml intratympanic 
gentamicin was administered. Intratympanic gentamicin is widely 
used for the control of vertigo in most Menière’s patients, with re-
ported success rates of 83% –91% [7].
Gentamicin has a high affinity for type I vestibular hair cells (dark cells), 
and therefore, produces relatively more vestibular impairment than 
hearing loss [8]. In 2014, Daneshi et al. [9] showed that one-shot low dos-
age gentamicin causes complete vertigo cessation in 58.3%. In 2001, 
Magnusson treated a group of patients with brainstem tumors with 
remaining vestibular function, who required surgery, with trans-tym-
panic gentamicin injection before tumor surgery and then performed 
“prelesion rehabilitation” to ease postoperative symptoms [10].
In our case, gentamicin infiltration treatment provided excellent re-
sults for vestibular symptoms. However, a noxious effect on hearing is 
possible without the possibility to stop tumor growth. Consequently, 
accurate MRI follow-up to monitor tumor growth development is es-
sential for patients who are suited for this treatment.
The disappearance of vestibular symptoms after gentamicin admin-
istration could also be attributed to the action of central compen-
sation mechanisms. However, central compensation usually occurs 
after a longer period than the appearance of the symptoms. In the 
case described above, the disappearance of the symptoms occurred 
immediately after the administration of gentamicin and this implies 
that it is related to the effect of the treatment.
Informed Consent: Written informed consent was obtained from patient who 
participated in this study. 
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Figure 7. MRI After one year, which showed no growth of the tumor lesion
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